

# NIH GUIDE

---

---

## For Grants and Contracts

---

### NOTICE OF MAILING CHANGE

Check here if you wish to  
discontinue receiving this  
publication

Check here if your address has  
changed and you wish to con-  
tinue receiving this publication.  
Make corrections below and  
mail this page to:

NIH Guide  
Printing & Reproduction Branch  
National Institutes of Health  
Room B4BN08, Building 31  
Bethesda, Maryland 20892

---

U.S. DEPARTMENT OF HEALTH  
AND HUMAN SERVICES

OFFICIAL BUSINESS  
Penalty for Private Use, \$300

The NIH Guide announces scientific  
initiatives and provides policy and  
administrative information to indi-  
viduals and organizations who need to  
be kept informed of opportunities,  
requirements, and changes in extra-  
mural programs administered by the  
National Institutes of Health.

Vol. 19, No. 24  
June 29, 1990

First Class Mail Postages & Fees Paid PHS/NIH/OD Permit No. G-291
--

NOTICES OF AVAILABILITY (RFPs AND RFAs)

CENTRAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE CLINICAL TRIALS (RFP) ..... 1  
National Institute of Allergy and Infectious Diseases  
Index: ALLERGY, INFECTIOUS DISEASES

DCBDC SMALL RESEARCH GRANTS ON ANIMAL MODELS OF SOLID TUMORS  
(RFA CA-90-18) ..... 1  
National Cancer Institute  
Index: CANCER

ONGOING PROGRAM ANNOUNCEMENTS

NIMH FUNCTIONAL BRAIN IMAGING CENTERS FOR THE STUDY OF MENTAL  
DISORDER (PA-90-18) ..... 2  
National Institute on Mental Health  
Index: MENTAL HEALTH

NOTICES OF AVAILABILITY (RFPs AND RFAs)

CENTRAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE CLINICAL TRIALS

RFP AVAILABLE: RFP-NIH-NIAID-DAIDS-91-13

P.T. 34; K.W. 0715008, 0740075, 0710070, 0780010, 0755010

National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases (NIAID), NIH, has a requirement to perform routine and innovative immunologic and virologic assays to support AIDS vaccine trials undertaken by the NIAID AIDS Vaccine Clinical Trials Network. This NIAID-sponsored project will take approximately five (5) years to complete. A cost-reimbursement contract is anticipated, and one (1) award will be made.

This is an announcement for an anticipated Request for Proposal (RFP). RFP-NIH-NIAID-DAIDS-91-13 shall be issued on or about July 12, 1990, with a closing date tentatively set for September 12, 1990.

Requests for the RFP should be directed in writing to:

Ms. Jacqueline Johnson  
Contract Management Branch  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Control Data Building, Room 222P  
6003 Executive Blvd.  
Bethesda, MD 20892

To receive a copy of the RFP, please supply this office with two (2) self-addressed labels. All responsible sources may submit a proposal which will be considered.

This advertisement does not commit the Government to award a contract.

DCBDC SMALL RESEARCH GRANTS ON ANIMAL MODELS OF SOLID TUMORS

RFA AVAILABLE: CA-90-18

P.T. 34; K.W. 0715035, 0755020, 0710070

National Cancer Institute

Letter of Intent Receipt Date: September 1, 1990  
Application Receipt Date: October 10, 1990

INTRODUCTION

The Cancer Immunology Branch of the Division of Cancer Biology, Diagnosis, and Centers (DCBDC) of the National Cancer Institute (NCI) invites applications for small grants to develop and establish animal models of solid tumors of non-hemopoietic origin to improve our understanding of the complexities of the human immune response to these tumors. Models are sought which demonstrate similar biological characteristics to human cancer, and which could be used in future studies to analyze the immunobiology of host-tumor interactions. The present Request for Applications (RFA) announcement is for a single solicitation with a specified deadline (October 10, 1990) for receipt of applications and September 1, 1990, for receipt of letters of intent.

RESEARCH GOALS AND SCOPE

The goal of this initiative is to provide funds for the development of new, or further characterization of existing, animal models of solid tumors of non-hematopoietic origin which are relevant to human cancer. The initiative is not limited to small laboratory animals (e.g., mice); however, appropriate reagents, such as antibodies for cellular identification, must be available for the immunologic study of any animal model proposed.

The scope of this initiative may comprise the use of transgenic animals, mice with the severe combined immunodeficiency (SCID) defect, spontaneously arising tumors, transplantable tumors from the site of origin to the same site within the recipient, or other tumor systems developed by the applicant. Tumors induced by chemicals, viruses or radiation will be considered if the tumor type exhibits characteristics analogous to a human tumor. Animal models which

utilize congenitally athymic (nude) mice where human tumors are injected subcutaneously into these mice primarily for maintaining the tumor will be excluded from review, and those applications will be returned to the applicant.

#### MECHANISM OF SUPPORT

Support of this program will be through the National Institutes of Health (NIH) grant-in-aid. Applicants will be responsible for the planning, direction, and execution of the proposed project. Except as otherwise stated in this RFA, awards will be administered under PHS policy as stated in the Public Health Service Grants Policy statement, DHHS Publication No. (OASH) 82-50,000, revised January 1, 1987. This RFA is a one-time solicitation.

The small grants (R03) mechanism provides research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable. Furthermore, the time interval from application to funding is shortened under the R03 mechanism; thus allowing new ideas to be investigated or pursued in a more expeditious manner.

Approximately \$700,000 in total costs per year for three years will be committed specifically to fund applications which are submitted in response to this RFA. The total direct costs per application may not exceed \$50,000 per year. It is anticipated that approximately 10 awards will be made. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. The total project period for applications submitted in response to this RFA should be at least one (1) year and may not exceed two (2) years. The earliest feasible start date for awards will be April 1, 1991. Although this program is provided for in the financial plans of the NCI, the award of grants pursuant to this RFA is also contingent upon the availability of funds for this purpose.

#### INQUIRIES

Prospective applicants are strongly encouraged to discuss their ideas with Dr. John Finerty (see below) to determine whether they fit the definition and guidelines of this announcement. The Program Director welcomes the opportunity to discuss this RFA with potential applicants. For further information, prospective applicants should contact:

Dr. John F. Finerty  
Program Director  
Cancer Immunology Branch  
National Cancer Institute  
National Institutes of Health  
Executive Plaza South, Room 634  
6120 Executive Boulevard  
Rockville, MD 20892  
Telephone: (301) 496-7815  
FAX: 301-496-8656

#### ONGOING PROGRAM ANNOUNCEMENTS

##### NIMH FUNCTIONAL BRAIN IMAGING CENTERS FOR THE STUDY OF MENTAL DISORDER

PA: PA-90-18

P.T. 34; K.W. 0706030, 0705010, 0715129

National Institute on Mental Health

The purpose of this announcement is to establish core resource Centers dedicated to multidisciplinary research using Positron Emission Tomography (PET) methodology in conjunction with other existing brain imaging technologies. The Center Grant will provide support for purchasing the necessary equipment to establish a PET capability or, where such capability already exists, support will be provided to assure access to such equipment by mental health researchers.

Applications may be submitted by any public or private, nonprofit or for-profit organization, including units of State and local governments. Women and minority investigators are especially encouraged to apply.

Applicants are urged to consider the inclusion of minorities and women in study populations for all research efforts. If they are not to be included, a clear rationale for their exclusion should be provided.

It is estimated that approximately \$5 million will be available to support approximately two new grants under this announcement in fiscal year 1991. The exact amount will depend on appropriated funds, the quality of proposals, and program priorities at the time of the award.

Applications will be assigned following the usual PHS referral guidelines.

To qualify for fiscal year 1991 funding, applications must be submitted by October 1, 1990. In subsequent years, a similar timetable will be in effect, using the October 1 receipt date.

Prior to submission, applicants are encouraged to contact:

Henry Khachaturian, Ph.D.  
Neuroimaging and Applied Neuroscience Research Branch  
Division of Basic Brain and Behavioral Sciences  
National Institute of Mental Health  
Room 11-105, Parklawn Building  
5600 Fishers Lane  
Rockville, MD 20857  
Telephone: (301) 443-3948

\*\*THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS:

5333 Westbard Avenue  
Bethesda, Maryland 20816